Legend Biotech (LEGN) Invested Capital (2019 - 2026)

Legend Biotech (LEGN) has reported Invested Capital for 8 consecutive years, with $266.0 million the latest figure, recorded in Q1 2026.

• Quarterly Invested Capital rose 6.4% year-over-year to $266.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 14.99% YoY) and the FY2025 annual result came in at $319.1 million, up 27.64% from the prior year.
• Invested Capital retreated to $266.0 million in Q1 2026 per LEGN's latest filing, from $319.1 million in the prior quarter.
• Over the last five years, Invested Capital for LEGN reached as high as $398.9 million in Q4 2022 and fell as low as $250.0 million in Q2 2023.
• A 5-year average of $273.0 million and a median of $250.0 million in 2023 frame the typical range for Invested Capital.
• Annual changes were most pronounced in 2022 — Invested Capital jumped 69.84% — and 2023, when it sank 37.33%.
• Year by year, Invested Capital stood at $398.9 million in 2022, then plunged by 37.33% to $250.0 million in 2023, then changed by 0.0% to $250.0 million in 2024, then gained by 27.64% to $319.1 million in 2025, then slipped by 16.64% to $266.0 million in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $266.0 million, $319.1 million, and $314.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.